FDA panel to review risk reclassification of electroshock systems

01/24/2011 | New York Times (tiered subscription model), The

An FDA panel will hold a meeting beginning Thursday to discuss whether to reclassify electroshock devices, which are used to treat major depression, from the high-risk category to medium-risk. The FDA review comes amid calls from specialists and psychiatric groups, including the American Psychiatric Association, for the downgraded device designation.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ